Back to Journals » Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (184)
- Volume 15, 2024 (12)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Journal Articles:
- 184 records -
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:115-121
Published Date: 9 July 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA
Lung Cancer: Targets and Therapy 2024, 15:87-114
Published Date: 22 June 2024
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
Lee JB, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:81-85
Published Date: 25 May 2024
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:75-80
Published Date: 23 May 2024
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
Luo FX, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:69-73
Published Date: 18 May 2024
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
González-Cao M, Cai X, Bracht JWP, Han X, Yang Y, Pedraz-Valdunciel C, Morán T, García-Corbacho J, Aguilar A, Bernabé R, De Marchi P, Sussuchi da Silva L, Leal LF, Reis RM, Codony-Servat J, Jantus-Lewintre E, Molina-Vila MA, Cao P, Rosell R
Lung Cancer: Targets and Therapy 2024, 15:55-67
Published Date: 9 May 2024
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Kaakour D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:49-54
Published Date: 23 April 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:41-47
Published Date: 12 April 2024
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Dou XJ, Ma RY, Ren DW, Liu Q, Yan P
Lung Cancer: Targets and Therapy 2024, 15:29-40
Published Date: 25 March 2024
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu’s Approach
Wang B, Wang J, Sun T, Ding Y, Li S, Lu H
Lung Cancer: Targets and Therapy 2024, 15:9-17
Published Date: 2 February 2024
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:1-8
Published Date: 25 January 2024
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:101-109
Published Date: 12 December 2023
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F
Lung Cancer: Targets and Therapy 2023, 14:85-99
Published Date: 21 November 2023
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M
Lung Cancer: Targets and Therapy 2023, 14:79-84
Published Date: 9 October 2023
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:71-78
Published Date: 7 July 2023
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:63-69
Published Date: 23 June 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:57-62
Published Date: 22 June 2023
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD
Lung Cancer: Targets and Therapy 2023, 14:47-55
Published Date: 19 May 2023
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Lee ATM, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:41-46
Published Date: 25 April 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Zhang SS, Lee A, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:27-30
Published Date: 19 April 2023
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A
Lung Cancer: Targets and Therapy 2023, 14:11-25
Published Date: 3 February 2023
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Brazel D, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:1-9
Published Date: 5 January 2023
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Brazel D, Arter Z, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:75-80
Published Date: 10 November 2022
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:67-73
Published Date: 25 October 2022
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW
Lung Cancer: Targets and Therapy 2022, 13:53-66
Published Date: 5 September 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:47-52
Published Date: 19 May 2022
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Brazel D, Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:33-45
Published Date: 13 May 2022
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:23-31
Published Date: 26 April 2022
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:13-21
Published Date: 29 March 2022
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Davis A, Ke H, Kao S, Pavlakis N
Lung Cancer: Targets and Therapy 2022, 13:1-12
Published Date: 2 March 2022
The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers
Vokes NI, Zhang J
Lung Cancer: Targets and Therapy 2021, 12:139-149
Published Date: 2 December 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:133-138
Published Date: 2 December 2021
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Fitzpatrick O, Naidoo J
Lung Cancer: Targets and Therapy 2021, 12:123-131
Published Date: 2 November 2021
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:115-122
Published Date: 7 October 2021
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:103-114
Published Date: 7 October 2021
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H
Lung Cancer: Targets and Therapy 2021, 12:93-102
Published Date: 30 August 2021
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer
Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R
Lung Cancer: Targets and Therapy 2021, 12:81-92
Published Date: 16 August 2021
Targeting AXL in NSCLC
Zaman A, Bivona TG
Lung Cancer: Targets and Therapy 2021, 12:67-79
Published Date: 10 August 2021
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Zhang SS, Zhu VW
Lung Cancer: Targets and Therapy 2021, 12:61-65
Published Date: 12 July 2021
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Shukla N, Hanna N
Lung Cancer: Targets and Therapy 2021, 12:51-60
Published Date: 28 June 2021
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
Fujino T, Suda K, Mitsudomi T
Lung Cancer: Targets and Therapy 2021, 12:35-50
Published Date: 20 May 2021
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Giustini N, Bazhenova L
Lung Cancer: Targets and Therapy 2021, 12:21-34
Published Date: 25 March 2021
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW
Lung Cancer: Targets and Therapy 2021, 12:11-20
Published Date: 18 March 2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Yu D, Zhao W, Vallega KA, Sun SY
Lung Cancer: Targets and Therapy 2021, 12:1-10
Published Date: 5 February 2021
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B
Lung Cancer: Targets and Therapy 2020, 11:113-121
Published Date: 18 December 2020
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
Nagata I, Ogino T, Arimura T, Yoshiura T
Lung Cancer: Targets and Therapy 2020, 11:105-111
Published Date: 9 October 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Lung Cancer: Targets and Therapy 2020, 11:73-103
Published Date: 7 October 2020
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Lung Cancer: Targets and Therapy 2020, 11:59-71
Published Date: 7 September 2020